The low HOXB-AS3-peptide level is correlated with a poor prognosis in CRC patients, and HOXB-AS3-peptide represses colorectal cancer (CRC) growth in vitro and in vivo. This evidence concerns the gene HOXB-AS3 and colorectal carcinoma.